Literature DB >> 25785066

A new model for the discrimination between ulcerative colitis and Crohn's disease.

Zhe Shen1, Wei-Ping Ma2, Xiao-Na Shao1, Chao-Hui Yu1, Juan Du1, Zun Xiang1, Gan-Hua Guo3, Hong Zhang4, You-Ming Li1, Min Yue1.   

Abstract

Distinguishing ulcerative colitis (UC) from Crohn's disease (CD) is sometimes difficult in a clinical setting. The purpose of this study was to identify a series of independent serum markers capable of distinguishing between UC and CD. 140 UC and 174 CD patients hospitalized at The First Affiliated Hospital, College of Medicine, Zhejiang University were recruited into this study. A panel of serum markers was quantified for each patient and the Bayesian information criterion (BIC) was used to determine a discrimination model. The receiver operating characteristic (ROC) was used to evaluate the performance of the model, and the area under the ROC curve (AUC) was used to evaluate the accuracy of the model. Serum albumin (Alb), total cholesterol (TC), total calcium (TCa), platelet (Plt), glycyl proline dipeptidyl aminopeptidase (GPDA) and their ratios (Alb: Plt, Alb: GPDA, TCa: TC, and Plt: GPDA) were selected into the diagnosis model using BIC. The resulting CD/UC Index (CUI) is CUI = 1.901 + 0.425 Alb - 3.324 TC - 7.444 TCa + 0.018 Plt + 0.087 GPDA - 0.0007 Alb: Plt - 0.004 Alb: GPDA + 1.839 TC: TCa + 0.003 Plt: GPDA, with CUI > 0 incrementally favored a diagnosis of UC, while CUI < 0 corresponded to a higher likelihood of a diagnosis of CD. An average value of the AUC for the CUI model is 0.73 (95% confidence interval: 0.67-0.80). The CUI, derived from commonly available serum biomarkers, could try to differentiate UC from CD in patients with unclear clinical features as a new approach to diagnosis.

Entities:  

Keywords:  Crohn’s disease; Ulcerative colitis; diagnostic model; serum biomarkers

Year:  2015        PMID: 25785066      PMCID: PMC4358521     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  27 in total

1.  Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients.

Authors:  Yufang Wang; Qin Ouyang
Journal:  J Gastroenterol Hepatol       Date:  2007-09       Impact factor: 4.029

2.  What is the role and significance of serum and stool biomarkers in the diagnosis of IBD?

Authors:  Ron Palmon; Steven J Brown; Maria T Abreu
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

3.  Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis.

Authors:  E A Fagan; R F Dyck; P N Maton; H J Hodgson; V S Chadwick; A Petrie; M B Pepys
Journal:  Eur J Clin Invest       Date:  1982-08       Impact factor: 4.686

4.  Biological markers in inflammatory bowel disease: practical consideration for clinicians.

Authors:  J L Mendoza; M T Abreu
Journal:  Gastroenterol Clin Biol       Date:  2009-06

5.  A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide.

Authors:  V K Hopsu-Havu; G G Glenner
Journal:  Histochemie       Date:  1966

Review 6.  The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.

Authors:  James D Lewis
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

7.  Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease.

Authors:  M C Dubinsky; J J Ofman; M Urman; S R Targan; E G Seidman
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

8.  Glycylprolyl-p-nitroanilidase in hepatobiliary disease.

Authors:  D R Hutchinson; R P Halliwell; J D Lockhart; D V Parke
Journal:  Clin Chim Acta       Date:  1981-01-08       Impact factor: 3.786

Review 9.  C-reactive protein as a marker for inflammatory bowel disease.

Authors:  Séverine Vermeire; Gert Van Assche; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-09       Impact factor: 5.325

Review 10.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.